Alzheimer’s disease highlighted with green marker, under the title Alzheimer’s

(© Ivelin Radkov - stock.adobe.com)

Dementia Early Warning Signs May Hide Outside the Memory Center

In A Nutshell

  • The amygdala, the brain’s fear center, shrank about twice as fast as the memory-linked hippocampus in scans from 1,149 volunteers.
  • A neighboring region, the entorhinal cortex, shrank fastest, up to 2.6 times the hippocampus rate in the larger study’s dementia group.
  • The part of the amygdala that shrank least also had the fewest tau tangles in autopsy tissue.
  • Adding both regions modestly improved early detection, but the approach is not ready to serve as a screening test.

A brain region best known for processing fear loses tissue faster in Alzheimer’s disease than the hippocampus, the memory center that has long dominated Alzheimer’s research. In brain scans from 1,149 volunteers, the amygdala, an almond-shaped structure deep in the brain, shrank about twice as fast as the hippocampus in the larger of two studies. The pattern appeared in every group measured, from healthy older adults to people with Alzheimer’s dementia.

A neighboring strip of tissue called the entorhinal cortex, closely wired to the hippocampus, shrank faster still, outpacing the hippocampus by up to 2.6 times in the larger study’s dementia group. Johns Hopkins University researchers reported the results in Neuroimage: Reports.

Autopsy studies have long placed the entorhinal cortex among the first areas hit by Alzheimer’s, while the amygdala has drawn less attention. With new therapies and trials targeting the disease’s underlying biology, spotting damage early matters more. Treatments may work best before much tissue is lost, and the amygdala may be an overlooked place to look.

Scans From 1,149 People Tracked Alzheimer’s Amygdala Shrinkage

Two long-running research projects supplied the scans. One, known as ADNI (the Alzheimer’s Disease Neuroimaging Initiative), launched in 2003 and supplied 1,019 participants. The other, BIOCARD, began in 1995 and supplied 130. Average starting ages ran from the late 60s to the mid-70s, and everyone had at least three MRI scans taken over time, so shrinkage could be tracked year by year.

Volunteers ranged from healthy older adults to people with dementia. In the larger project, 387 were comparison volunteers without impairment, 523 had mild cognitive impairment, a stage of memory and thinking trouble that is often an early warning sign of Alzheimer’s, and 109 had dementia. The smaller project included healthy volunteers and people at each of those stages.

Instead of outlining every scan by hand, researchers used a computer program trained on hundreds of expert-traced scans to mark each brain structure. Its outlines overlapped closely with human experts’ work, though the thin, layered entorhinal cortex proved harder to trace than the other two structures.

brain dementia
This work demonstrates that the entorhinal cortex, in blue, and the amygdala, in red, predict early Alzheimer’s disease better than the hippocampus, shown in green. Credit: Johns Hopkins University

Amygdala and Entorhinal Shrinkage Outpaced the Hippocampus at Every Stage

Both sides of the brain and both projects showed the same ranking, with the hippocampus shrinking least. In the larger project’s dementia group, the hippocampus shrank roughly 3 percent a year, the amygdala roughly 7 percent and the entorhinal cortex roughly 8 percent.

That gap opened early, too. Among healthy participants in the smaller project, the hippocampus barely changed, losing only 0.04 percent a year, while the amygdala lost about 1.3 percent, a gap visible even in people with no diagnosis. Scanner brands did not significantly change shrinkage rates in the larger project, which makes equipment differences an unlikely explanation.

Because the amygdala also helps drive anxiety, stress and mood, damage there could help explain why some people with Alzheimer’s show emotional and behavioral changes, though this study did not test that idea.

Alzheimer’s Amygdala Shrinkage Followed Tau Buildup Patterns

Alzheimer’s disease is closely tied to tangles of a protein called tau, which builds up abnormally inside brain cells. To see whether shrinkage lined up with that damage, the team split the amygdala into four regions using a detailed brain map. In people with mild impairment or dementia from the larger project, three regions lost roughly 6 to 8 percent a year. A fourth, along the outer edge, lost only about 2.5 percent.

That outer region also had the fewest tau tangles in an autopsy sample from earlier work by the same group, so shrinkage mirrored where tau tangles were densest. Tau scans of living people pointed the same direction: in the entorhinal cortex and hippocampus, higher tau readings tended to go with faster shrinkage. Thinning of the entorhinal cortex’s layers also tracked its volume loss, evidence that the scans capture real tissue damage, not measurement noise.

Adding the Amygdala Modestly Improved Early Detection

Researchers next tested whether the amygdala and entorhinal cortex could help spot early trouble. Using 346 healthy ADNI volunteers and 210 with early mild cognitive impairment, they compared a model built on the hippocampus alone with one that added the other two regions. On a scale where 0.5 is a coin flip and 1.0 is perfect, the combined model scored 0.665, versus 0.635 for the hippocampus alone. The gain was statistically significant and came mostly from fewer healthy people being wrongly flagged, about 8 percentage points fewer on average, with a similar share of true early cases still caught.

Still, accuracy remained moderate, and the approach is not ready to serve as a stand-alone screening test. The comparison pitted people already diagnosed with early impairment against healthy volunteers, so whether these scans can flag Alzheimer’s before symptoms appear remains untested.

Alzheimer’s research has spent decades concentrating on the hippocampus. Measuring the amygdala and entorhinal cortex alongside it is now worth doing, because both outpaced it in two independent groups. Whether that catches the disease before memory fails will take studies that follow healthy people for many years.


Disclaimer: This article reports on a scientific study for informational purposes only and is not medical advice. Anyone with concerns about memory or brain health should consult a qualified health professional.


Paper Notes

Limitations

Participants came from two research projects, and the paper’s tables report age and scan counts but not sex or racial makeup, so how well the results apply to other populations is unclear. The study is observational, so it shows associations between shrinkage and tau rather than proving cause. Group sizes varied widely, including only 8 people with dementia in BIOCARD. The authors note that the entorhinal region is difficult to measure on MRI because of its thin, layered structure and its closeness to fluid-filled spaces, which can confuse automated tracing even when overall accuracy is high. Distinguishing cognitively normal participants from those with early mild cognitive impairment was only moderate, which the authors link to how subtle brain changes are at that stage. The tau comparisons with the amygdala relied on a postmortem sample from earlier work, and definitions of amygdala subregions vary across studies, so comparisons with prior autopsy research call for caution. The classification compared early mild cognitive impairment with healthy participants, so it did not test whether the measures predict who later develops Alzheimer’s. The authors also report that they do not have permission to share the data.

Funding and Disclosures

Funding came from the National Institutes of Health, the National Science Foundation and the Kavli Neuroscience Discovery Institute. BIOCARD is supported by the National Institute on Aging and led by Dr. Marilyn Albert at Johns Hopkins School of Medicine. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Department of Defense and contributions from multiple private pharmaceutical and technology companies, coordinated through the Foundation for the National Institutes of Health. Author Michael I. Miller reported a relationship with AnatomyWorks that includes equity. The remaining authors declared no known competing financial interests.

Publication Details

Study title: “Rostral associations of MRI atrophy of the amygdala and entorhinal cortex across the AD spectrum.” Published in Neuroimage: Reports, Volume 6 (2026), article 100392, available online August 10, 2026, as an open access article under a CC BY license. Authors: Michael I. Miller, Yi Xie, Kaitlin M. Stouffer, Can Ceritoglu, Jiabei Li, J. Tilak Ratnanather, Laurent Younes, Arnold Bakker, Nisha Rani, Marilyn S. Albert, Juan C. Troncoso and Meaghan Morris, for the Alzheimer’s Disease Neuroimaging Initiative. Corresponding author: Yi Xie, Department of Electrical and Computer Engineering, Johns Hopkins University. Additional affiliations include the Johns Hopkins departments of Biomedical Engineering, Neurology, Psychiatry and Behavioral Sciences, Pathology and Computer Science, plus the Center for Imaging Science and the Kavli Neuroscience Discovery Institute. DOI: 10.1016/j.ynirp.2026.100392

About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor